This feature of HER2 positivity in bladder cancer predicts BCG unresponsiveness, providing a potential basis for using immune checkpoint inhibitors or HER2 therapeutics in conjunction with BCG in the initial treatment phase for BCG naive bladder cancer patients. Here, ERBB2 is linked to urinary bladder carcinoma.